Myomo Q2 adjusted EBITDA loss narrows, beats expectations
Myomo Q2 adjusted EBITDA loss narrows, beats expectations
Overview
Wearable medical robotics firm's Q2 revenue rose 21% yr/yr on higher ASP and unit sales
Q2 adjusted EBITDA loss narrowed and beat analyst expectations
Company raised full-year revenue guidance to $45-47 mln
Outlook
Myomo sees Q3 2026 revenue between $11.5 mln and $12.0 mln, up 14%-19% year-over-year
Company raises full-year 2026 revenue guidance to $45 mln to $47 mln
Myomo expects cash burn to be less than $2 mln in H2 2026
Result Drivers
RECURRING PATIENT SOURCES - 53% of Q2 revenue came from recurring sources like provider referrals, O&P partners, and the VA, up from 26% a year ago
HIGHER ASP AND UNIT SALES - Q2 revenue growth reflected a higher average selling price and a 19% increase in MyoPro units recognized as revenue
COST REDUCTIONS - Gross margin improvement was driven by higher ASP and cost reductions, including the rollout of the Myomo Mobile App, partially offset by higher clinical costs
Company press release: ID:nBw4VvvXwa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.09 |
|
Q2 Net Loss |
| $4.02 mln |
|
Q2 Adjusted EBITDA | Beat | -$827,282 | -$3.16 mln (3 Analysts) |
Q2 Operating Expenses |
| $10.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Myomo Inc is $3.00, about 177.8% above its August 4 closing price of $1.08
Reuters Recommended Reads
Aug 4 - Procept BioRobotics Q2 revenue beats estimates on HYDROS demand
Aug 4 - Hinge Health Q2 revenue jumps 53%, beats estimates
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)